CANNAINVESTOR Magazine May / June 2017 - Page 25

-Clinical data provides conclusive evidence for the treatment of chronic pain and neuropathic pain

-Neuropathic is not well controlled with current treatments

-Adverse effect of opiates include respiratory depression

-Opioid overdose mortality rates reported to be 24.8% lower in US states with medical cannabis laws

-Canadian study showed chronic pain patients had no greater risk than non-users to experience serious adverse events

-Significant reduction in opioid use – 44% to 65% reduction cited

-Cannabinoids and opioids share several pharmacologic properties and may act synergistically

AusCann is initially targeting neuropathic and chronic pain. A combined market opportunity of >$5 billion in Australia alone

Source: Company calculations based upon $5 per day – approx. $1825/yr

25

TARGET MARKETS AND OPPORTUNITY